Please check your internet connection and try again.
# Septran (co-Trimoxazole)
## Overview
Septran is a combination antibiotic containing sulfamethoxazole and trimethoprim. It is a bacteriostatic agent that inhibits folic acid synthesis.
## Primary Indications
* **Urinary Tract Infections (UTIs):** Acute uncomplicated UTIs, prophylaxis in recurrent UTIs.
* **Pneumocystis jirovecii Pneumonia (PJP):** Treatment and prophylaxis.
* **Shigellosis:** Treatment of antibiotic-susceptible Shigella infections.
* **Otitis Media:** Treatment of acute otitis media in children.
* **Traveler's Diarrhea:** Prophylaxis and treatment.
## Adult Dosing
* **Uncomplicated UTIs:** 1 double-strength (DS) tablet (160 mg trimethoprim/800 mg sulfamethoxazole) every 12 hours for 3-7 days.
* **PJP Treatment:** 15 mg/kg/day of trimethoprim component, divided into 3-4 doses, administered orally or IV over 14-21 days. Maximum 800 mg trimethoprim component per dose.
* **PJP Prophylaxis:** 1 DS tablet (160 mg trimethoprim/800 mg sulfamethoxazole) daily, or 1 DS tablet three times weekly (intermittent therapy).
* **Shigellosis:** 1 DS tablet (160 mg trimethoprim/800 mg sulfamethoxazole) every 12 hours for 5 days.
* **Traveler's Diarrhea Prophylaxis:** 1 DS tablet daily during travel.
## Pediatric Dosing
* Dosing is based on the trimethoprim component.
* **UTIs and Shigellosis:** 8 mg/kg/day of trimethoprim component, divided into 2 doses. Maximum dose is 160 mg trimethoprim per dose (equivalent to 1 DS tablet). Administer for 5 days for shigellosis, 3-7 days for UTIs.
* **Otitis Media:** 8 mg/kg/day of trimethoprim component, divided into 2 doses for 10 days.
* **PJP Treatment:** 15 mg/kg/day of trimethoprim component, divided into 3-4 doses, over 14-21 days.
* **PJP Prophylaxis:** 75 mg/m²/day of trimethoprim component, divided into 2 doses, on 3 days per week (e.g., Monday, Tuesday, Wednesday).
## Dose Adjustments
* **Renal Impairment:** Dose adjustment is necessary based on CrCl. Consult specific guidelines for detailed recommendations.
* CrCl > 30 mL/min: No adjustment needed.
* CrCl 15-30 mL/min: Administer 75% of the usual dose.
* CrCl < 15 mL/min: Avoid use. If unavoidable, administer 50% of the usual dose every 12 hours.
## Contraindications
* Known hypersensitivity to trimethoprim or sulfonamides.
* Documented severe adverse reaction (e.g., Stevens-Johnson syndrome) to sulfonamides.
* Megaloblastic anemia due to folate deficiency.
* Infants less than 2 months of age (risk of kernicterus).
* Severe renal or hepatic insufficiency when plasma concentrations cannot be monitored.
## Adverse Effects
* **Common:** Nausea, vomiting, rash (especially in HIV-positive patients), hyperkalemia.
* **Serious:** Stevens-Johnson syndrome, toxic epidermal necrolysis, aplastic anemia, agranulocytosis, severe rash (DRESS), photosensitivity, renal impairment, hyperkalemia.
## Key Drug Interactions
* **Warfarin:** Increased INR. Monitor INR closely and adjust warfarin dose.
* **ACE Inhibitors/ARBs/Potassium-Sparing Diuretics:** Increased risk of hyperkalemia. Monitor potassium levels.
* **Methotrexate:** Increased methotrexate levels, potentially leading to toxicity.
* **Digoxin:** Increased digoxin levels. Monitor digoxin levels.
* **Potassium Supplements:** Increased risk of hyperkalemia.
* **Rifampin:** May decrease serum levels of co-trimoxazole.
## Monitoring
* **Renal Function:** Especially in patients with pre-existing renal disease or those receiving concurrent nephrotoxic agents.
* **Electrolytes:** Particularly potassium levels, especially in patients with renal impairment or receiving other drugs that affect potassium.
* **Complete Blood Count (CBC):** Monitor for hematologic abnormalities (e.g., leukopenia, thrombocytopenia, anemia), especially with prolonged use or in immunocompromised patients.
* **Liver Function Tests (LFTs):** Periodically, especially in patients with impaired liver function.
* **Therapeutic Drug Monitoring:** May be considered in specific situations (e.g., severe infections, PJP treatment).
## Clinical Pearls
* Administer with food or milk to minimize gastrointestinal upset.
* Ensure adequate hydration to prevent crystalluria.
* Sulfonamides can displace bilirubin from albumin; avoid in newborns and in pregnant women near term.
* Co-trimoxazole can cause a false-positive urine glucose test; use a glucose-specific method if necessary.
* Rash is a common adverse effect and may necessitate discontinuation of therapy.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and local protocols for definitive guidance.*
